Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma.

被引：0
|
作者：
Uziel, O
Shapira, A
Radnay, J
Lahav, M
Lishner, M
机构：
[1] Sapir Med Ctr, Oncogenet Lab, Kefar Sava, Israel
[2] Sapir Med Ctr, Hematol Lab, Kefar Sava, Israel
[3] Sapir Med Ctr, Dept Med, Kefar Sava, Israel
[4] Tel Aviv Univ, IL-69978 Tel Aviv, Israel
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1573
引用
收藏
页码：373A / 374A
页数：2
相关论文
共 50 条
  • [21] Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma.
    Hattori, Y
    Kakimoto, T
    Okamoto, S
    Iguchi, T
    Morita, K
    Tanigawara, Y
    Ikeda, Y
    BLOOD, 2003, 102 (11) : 689A - 689A
  • [22] Intermittent low doses of thalidomide in the maintenance treatment of multiple myeloma.
    Bibas, M
    Andriani, A
    Viva, F
    Gualandi, C
    Mignogna, T
    Geraldini, C
    Tarquini, D
    BLOOD, 2004, 104 (11) : 313B - 314B
  • [23] Optimization of PCR Conditions for Amplification of GC-Rich EGFR Promoter Sequence
    Obradovic, Jasmina
    Jurisic, Vladimir
    Tosic, Natasa
    Mrdjanovic, Jasminka
    Perin, Branislav
    Pavlovic, Sonja
    Djordjevic, Natasa
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2013, 27 (06) : 487 - 493
  • [24] Thalidomide plus melphalan in relapsed-refractory multiple myeloma.
    Offidani, M
    Mele, A
    Marconi, M
    Corvatta, L
    Candela, M
    Pieroni, S
    Malerba, L
    Rupoli, S
    Olivieri, A
    Leoni, P
    BLOOD, 2001, 98 (11) : 311B - 311B
  • [25] Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
    Kumar, S
    Witzig, TE
    Wellik, L
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Kyle, RA
    Gertz, MA
    Greipp, PR
    Rajkumar, SV
    BLOOD, 2003, 102 (11) : 387B - 387B
  • [26] Single dose pharmacokinetic study of thalidomide in patients with multiple myeloma.
    Pathak, A.
    Malhotra, J.
    Raina, V
    Arya, D. S.
    Gupta, Y. K.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 218 - 218
  • [27] Isolation of differentially expressed genes in multiple myeloma.
    Thertulien, R
    Michaeli, J
    Luzzatto, L
    BLOOD, 2000, 96 (11) : 154A - 155A
  • [28] Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma.
    Cavo, M
    Zamagni, E
    Tosi, P
    Cellini, C
    de Vivo, A
    Cangini, D
    Tonelli, M
    Testoni, N
    Grafone, T
    Tacchetti, P
    Soverini, S
    Terragna, C
    Tura, S
    Baccarani, M
    BLOOD, 2003, 102 (11) : 448A - 448A
  • [29] Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma.
    Devabhaktuni, YD
    Laber, DA
    BLOOD, 2002, 100 (11) : 384B - 384B
  • [30] Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.
    Tosi, P
    Ronconi, S
    Zamagni, E
    Cellini, C
    Tura, S
    Cavo, M
    BLOOD, 2000, 96 (11) : 296B - 296B
12345